Stop Flow in abdominal and pelvic cancer relapses

Rosario Vincenzo Iaffaioli,Gaetano Facchini, Anna Tortoriello, Feliciano Crovella,Giovannni Romano,Roberta Formato,Michele Santangelo,Emiddio Barletta,Francesco Fiore, Vittorio Iaccarino, Bruno Memoli,Roberto D'Angelo,Pier Luigi Pilati,Riccardo Rossi,Stefano Guadagni,Marcello Deraco,Sandro Pignata,Bruno Daniele,Gerardo Rosati,Bruno Massidda, Giovanni Mantovani,Enrico Di Salvo, Nicola Marzano, Vincenzo Memeo, Valerio Parisi,Giorgio Mallarini,Giuseppe Colucci

FRONTIERS IN BIOSCIENCE-LANDMARK（2006）

引用 4|浏览20

暂无评分

摘要

To determinate MTD, DLT and safe doses for phase II study, a dose finding study with Mitomicyn and Adriamycin Stop-Flow administration was carried out. A phase II study focused on resectability of pelvic colorectal relapses is in progress. From November 1995, 84 pts, 52 male and 32 female ( 94 treatments), with advanced not resectable abdominal ( 14 pts) or pelvic ( 70 pts) relapses, and resistant to previous systemic chemotherapy, were enrolled in the study. 46 pts entered the phase I-early phase II study, while subsequently 38 pts were recruited in ongoing phase II study. Safe dose were: MMC 20 mg/mq and ADM 75 mg/mq. The phase II study focused on colorectal relapses registered very promising responses: 90% pain control, 1 pCR and 26 PR / 63 ( OR 43%), 8 NC (13%) 9/27 responder patients (33%) obtained a complete resectability of colorectal relapses. Stop-Flow is a safe and feasible technique very useful as a palliation treatment.

查看译文

关键词

stop-flow,pelvic relapses,cancer,neoplasm,tumor,relapses,recurrence,pelvis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要